Merck & Moderna's Cancer Vaccine Breakthrough Marks New Hope for Patients
The development of cancer vaccines has been a long-standing goal for scientists, and recent breakthroughs show that mRNA technology may be on the cusp of fulfilling this quest. Merck & Co. and Moderna Inc.'s Phase 3 study combining their personalized mRNA-based vaccine intismeran with immunotherapy Keytruda has shown promising results in a large late-stage trial.
The study, which followed patients with melanoma, found that the addition of the vaccine to treatment with Keytruda lengthened the time before people's cancer returned and tumors appeared in other parts of the body. In June, the companies reported results from a smaller study that followed patients for five years, finding intismeran and Keytruda lowered the chances of melanoma returning or metastasizing by 49% compared to Keytruda alone.
While there is still much work to be done to show the potential of cancer vaccines beyond melanoma, this development marks a critical next chapter for the technology. mRNA has been shown to be effective in combatting infectious diseases, and its application in cancer treatment offers new hope for patients.